130 related articles for article (PubMed ID: 1954180)
1. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma.
Skov BG; Sørensen JB; Hirsch FR; Larsson LI; Hansen HH
Ann Oncol; 1991 May; 2(5):355-60. PubMed ID: 1954180
[TBL] [Abstract][Full Text] [Related]
2. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Carles J; Rosell R; Ariza A; Pellicer I; Sanchez JJ; Fernandez-Vasalo G; Abad A; Barnadas A
Lung Cancer; 1993 Dec; 10(3-4):209-19. PubMed ID: 7521264
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma.
McWilliam LJ; Manson C; George NJ
Br J Urol; 1997 Aug; 80(2):287-90. PubMed ID: 9284204
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms.
Lloyd RV; Mervak T; Schmidt K; Warner TF; Wilson BS
Am J Surg Pathol; 1984 Aug; 8(8):607-14. PubMed ID: 6205601
[TBL] [Abstract][Full Text] [Related]
7. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase.
Giovanella L; Ceriani L; Bandera M; Garancini S
Int J Biol Markers; 2001; 16(1):50-5. PubMed ID: 11288956
[TBL] [Abstract][Full Text] [Related]
8. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer.
Makretsov N; Gilks CB; Coldman AJ; Hayes M; Huntsman D
Hum Pathol; 2003 Oct; 34(10):1001-8. PubMed ID: 14608533
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation and prognosis in breast adenocarcinoma.
Miremadi A; Pinder SE; Lee AH; Bell JA; Paish EC; Wencyk P; Elston CW; Nicholson RI; Blamey RW; Robertson JF; Ellis IO
Histopathology; 2002 Mar; 40(3):215-22. PubMed ID: 11895486
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine marker expression in cervical carcinomas of non-small cell type.
Chavez-Blanco A; Taja-Chayeb L; Cetina L; Chanona-Vilchis G; Trejo-Becerril C; Perez-Cardenas E; Segura-Pacheco B; Acuña-González C; Dueñas-Gonzalez A
Int J Gynecol Pathol; 2002 Oct; 21(4):368-74. PubMed ID: 12352185
[TBL] [Abstract][Full Text] [Related]
11. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
Graziano SL; Mazid R; Newman N; Tatum A; Oler A; Mortimer JA; Gullo JJ; DiFino SM; Scalzo AJ
J Clin Oncol; 1989 Oct; 7(10):1398-406. PubMed ID: 2550590
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors.
Said JW; Vimadalal S; Nash G; Shintaku IP; Heusser RC; Sassoon AF; Lloyd RV
Hum Pathol; 1985 Mar; 16(3):236-40. PubMed ID: 3972403
[TBL] [Abstract][Full Text] [Related]
14. Correlation between chromogranin A, neuron-specific enolase and synaptophysin expression, and some clinico-pathological features of colorectal cancer.
Famulski W; Sulkowska M; Miller-Famulska D; Kisielewski W; Sulkowski S
Folia Histochem Cytobiol; 2001; 39(2):155-6. PubMed ID: 11374802
[TBL] [Abstract][Full Text] [Related]
15. Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.
Mjønes P; Sagatun L; Nordrum IS; Waldum HL
J Histochem Cytochem; 2017 Dec; 65(12):687-703. PubMed ID: 28972818
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase.
Rasmuson T; Grankvist K; Roos G; Ljungberg B
Acta Oncol; 1999; 38(5):623-8. PubMed ID: 10427952
[TBL] [Abstract][Full Text] [Related]
17. Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer.
O'Shea P; Cassidy M; Freaney R; McCarthy P; Fennelly J
Ir J Med Sci; 1995 Jan; 164(1):31-6. PubMed ID: 7890531
[TBL] [Abstract][Full Text] [Related]
18. Antigenic phenotype of lung carcinomas: usual spectrum of distribution of thyroid transcription factor-1, cytokeratin 7, cytokeratin 20, and neuron specific enolase--basic immunohistochemical study of 21 cases.
Kostovski M; Petrushevska G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2014; 35(1):199-207. PubMed ID: 24798606
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
